Skip to content
Subscriber Only

Glaxo Findings on Avandia Safety Supported in Reanalysis

A second look at GlaxoSmithKline Plc’s once-best-selling diabetes pill found it doesn’t increase overall cardiac death risk, U.S. regulators said.

Findings by London-based Glaxo that Avandia doesn’t raise the overall risk of death, heart attack or stroke appear to be supported in a reanalysis by independent researchers, some Food and Drug Administration staff said today in a report. FDA advisers will reconsider restrictions imposed on Avandia in 2010 at a meeting June 5-6, according to the report.